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On the second European Panel on the Appropriateness of
Crohn's disease Therapy (EPACT-II)In an era of evidence based medicine, what constitutes
“evidence”? For aficionados, a large, statistically powered
clinical trial that enrolls a specific type of patient,
randomized to receive one of several alternative therapies,
being evaluated in a blinded fashion would achieve that
status. Even better, if multiple trials examined the same
therapy in the same way, then a meta-analysis synthesizing
those data provides even better “evidence” for patients and
providers. In contrast, the second European Panel on the
Appropriateness of Crohn's disease Therapy (EPACT-II) –
reported in this issue of the JCC 1–4 – uses a very different
approach, developing clinical practice guidelines based upon
the consensus judgment of a multi-national expert panel.
This series of articles delineates the appropriateness of
specific therapeutic interventions in patients with a diversity
of Crohn's disease presentations. Comparing these two
approaches, is the former “evidence” and the latter
something else? For the practicing clinician and the patients
whom they treat, do both approaches have utility?
Clinical trials represent the gold standard evidence
required by regulatory groups such as the Food and Drug
Administration in the United States and the European Union's
European Medicines Agency. Prior to drug approval, these
entities evaluate the efficacy and safety results from
carefully designed and executed randomized trials. Trial
protocols specify inclusion criteria, characteristics of the
interventions, frequency of evaluation, and the metrics upon
which the study will be statistically judged. Trials require
years to complete, often at a cost exceeding 10–20 million
euros for each one. The results from these trials provide the
best answer to the proposed research question: in patients
with specific demographic and clinical characteristics (with
other patient groups consciously excluded from the study),
who receive a specific drug, given in a specific way, under
closely monitored care, when the patient does not have
financial responsibility for the medication, what is the
efficacy and safety of that medication? A randomized trial
has substantial internal validity (likelihood that the answer is
correct), but that result may not be generalizable or
applicable outside of that patient population who received
care in a very controlled environment. Would similar results
occur in older patients?, in those with more extensive1873-9946/$ - see front matter © 2009 European Crohn's and Colitis Org
doi:10.1016/j.crohns.2009.09.002disease?, when the patient is not fully compliant with the
regimen (due to inconvenience, forgetfulness, or cost)?, or
when dose adjustment occurs based upon differing criteria?
As an example, clinical trials have shown efficacy of
infliximab in patients with moderate–severe Crohn's disease
refractory to steroids. However, the patient sitting before
you typically differs, in some fashion, from the published
trial: perhaps a 37 year old woman with ileal Crohn's disease
who obtained remission on steroids (with difficulty), experi-
ences 2–4 relapses per year, previously failed both azathi-
oprine and 6MP but has not yet received methotrexate. In
this patient, would methotrexate provide the best outcome
or should the patient receive infliximab (or adalimumab)?
Would the outcomes on these potential drugs differ if she
were pregnant? No randomized trial comparing relevant
therapies in this patient population exists today; nor will
they in the future. Too many constellations of clinical factors
exist for enough trials to answer them all. For that reason,
clinicians will always need to apply judgment as they
examine an individual patient, review the relevant clinical
studies, and then determine what might be the most
appropriate intervention for him/her.
Rather than relying upon a single clinician and his
judgment, a consensus process harnesses the views of a
broader collection of individuals. Sometimes, consensus
documents are prepared informally and the results may be
suboptimal. In contrast, the RAND/UCLA Appropriateness
Method, employed by the authors of these articles, uses a
defined process and blends available evidence with a
quantitative synthesis of expert opinion. They developed a
series of 296 scenarios (or indications) with permutations of
factors such as: disease severity, location, response to prior
medications, the occurrence of adverse events to those
medications, and the current therapy being considered. A
broadly representative multidisciplinary group of clinicians
reviewed an evidence summary and rated the appropriate-
ness of each intervention in a quantitative fashion (each
panelist rated each scenario on a 9-point scale). In an effort
to balance each expert's viewpoint and avoid the bias of the
loudest or most frequently spoken advocate, each of the
panelists has equal weight in the statistical summaries
performed. This method also does not force agreement.anisation. Published by Elsevier B.V. All rights reserved.
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intervention for that scenario is labeled as “uncertain.”
Areas of uncertainty often arise where clinical data are
inadequate.
The RAND/UCLA Appropriateness Method has been used
frequently and studied methodologically. Over 100 publica-
tions have used this approach, and it has undergone
methodological validation, comparing the stability of indi-
vidual experts' ratings over time, consistency of ratings with
the underlying evidence, and the relationship between
ratings of “appropriate” vs. “inappropriate” and the out-
comes achieved by those patients.5,6 Although widely used,
any consensus method has limitations. When multiple expert
panels used the RAND approach and simultaneously devel-
oped guidelines on the same topic, agreement was rather
close among 3 separate coronary revascularization panels,
but less concordant for decisions regarding hysterectomy.7
Thus, any results based upon this technique must be viewed
in this context.
The EPACT-II created a categorization of clinical scenarios
for patients with Crohn's disease and the ratings provide an
assessment of therapeutic appropriateness. These catego-
rized scenarios have three potential uses. First, the scenarios
can target future clinical research. One quarter of the
scenarios was rated “uncertain”. This often occurs where
evidence is relatively unavailable. Having identified these
“uncertain” scenarios, future clinical studies could focus on
the corresponding patient groups and examine differential
outcomes based upon the therapies provided to them.
Second, an audit of Crohn's disease cases could ascertain
how often care meets criteria of appropriateness. Although
substantial resources are expended to care for this patient
population, are these patients receiving appropriate care?
Sometimes, guidelines are written as very broad statements
into which a diversity of patients may fit. The current effort
would place patients into discrete and mutually exclusive
categories where distinctions of appropriateness could be
made. A quantifiable chart audit could ascertain whether
current care meets an adequate threshold (e.g., b5% of
patients receive care rated as “inappropriate”).
Finally, these appropriateness ratings can be used
prospectively. Before taking a therapeutic decision, clin-
icians could enter a patient's specific clinical information
into the EPACT website (www.epact.ch) and determine
whether the proposed intervention was viewed as appropri-
ate by the EPACT panel.
In an ideal world, every patient's care would be based
upon highly specific randomized trial information thataccurately reflects their clinical characteristics and practice
environment. Since this vision is unobtainable, efforts like
those of the EPACT-II are an important adjunct, combining
what is known from high quality evidence with the consensus
assessment of experts. Understanding the limitations of their
work will enable it to be used in the most productive fashion.
These appropriateness criteria could guide decision making,
but should not be the final determinant of care.References
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